

#### REGISTRATION:

There is no fee for NJSHP members attending this program. NON-MEMBERS: Non-members wishing to attend will be charged a fee of \$100 (pharmacist) & \$25 (technician). Should the attendee wish to join the Society at this time, the fee will be credited toward the first year's dues. [NO REFUNDS](#)

RESERVATIONS ARE REQUIRED BY: October 3rd, 2019, by 12-noon: [CLICK HERE](#)

SEATING IS LIMITED TO 100 – PLEASE REGISTER EARLY! All members are welcome to attend. If you reserve but cannot attend, please notify us at 609-936-2205.

Meeting Cancellation: In case of inclement weather please call the office at 609-936-2205.

Target Audience: The target audience for pharmacist programs are pharmacists practicing in a wide variety of healthcare systems. The target audience for technician programs are technicians practicing in a wide variety of healthcare systems.

CONTINUING EDUCATION CREDIT: The New Jersey Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education, as a provider of continuing education. This program provides 7 contact hours of knowledge based continuing education credits for pharmacists and technicians.

At the end of the program, attendees will receive a post-meeting assessment in their email. Completion of this will be required to record participation. CE certificates will be available only to those who complete the post-meeting assessment. *NJSHP is now using CPE Monitor to record attendance at all of our ACPE accredited programs.*



Sponsors for the event:

Allergan  
Merck & Co., Inc.  
Portola

Thank you for your support!




## The New Jersey Society of Health-System Pharmacists North Chapter &



### Presents **THE 10<sup>th</sup> ANNUAL MEDICATION SAFETY SYMPOSIUM**

Saturday October 5<sup>th</sup>, 2019  
8:00 a.m. – 4:30 p.m.



St. Joseph's University Medical  
Center  
Auditoriums 1-3  
Paterson, NJ 07503

[Directions](#)

#### PROGRAM AGENDA

8:00 - 8:15 a.m.

##### Registration/Continental Breakfast

8:15 - 8:30 a.m.

##### Welcome/Opening Remarks

Neli Attas, RPh, PharmD, AE-C

8:30 - 9:30 a.m. (1 CE)

##### Medication Safety Pearls - Session 1

Maria Heaney, PharmD

Antibiotic-Induced C. diff: Giving you a Run for your Money

Danielle Tomkins, PharmD, BCCCP

Strategies to Reduce Medication Errors Involving Continuous Infusions in the Intensive Care Unit

Michael T. Mauri, PharmD, BCPS

Preventing Medication Errors Related to Anticoagulant Use and Dispensing

Jane You, PharmD

Update on The Joint Commission's National Patient Safety Goal for Anticoagulation Therapy

9:30 - 10:30 a.m. (1 CE)

##### Updates and Controversies Surrounding Medical Cannabis:

##### What Pharmacists Need to Know

Mary Bridgeman, PharmD, BCPS, BCGP

10:30 - 11:30 a.m. (1 CE)

##### "How Low Ca(Na+) You Go? Hyponatremia Management and Patient Safety Considerations"

Jackie P. Johnston, PharmD, BCPS

Christine Pham, PharmD, PGY1 Pharmacy Resident

##### Exhibitor Session and Lunch - 11:30 a.m. - 12:30 p.m.

12:30 - 1:30 p.m. (1 CE)

##### "Technology: EHR E-Utopia: Are We There Yet?"

Radhika Pisupati, PharmD, BCPS

Michelle Cottino, PharmD, PGY1 Pharmacy Resident

1:30 - 2:30 p.m. (1 CE)

##### Medication Safety Pearls - Session 2

Ken Biason, PharmD, BCPS

High-Dose Extended Interval Aminoglycoside Dosing

Umme Honey, PharmD, BCPS

Post-exposure Prophylaxis (PEP) for Occupational HIV Exposure

Lynette Richards, PharmD, BCPS

T.H.I.N.K. Delirium

Safia Kuriakose, PharmD, BCPS AQ-ID

Breakthrough in Ebola Treatment

2:30 - 3:30 p.m. (1 CE)

##### Medication Safety Considerations in Prostate Cancer

Christopher Malabanan, PharmD, BCPS

Kelvin Reynolds, PharmD, PGY1 Pharmacy Resident

3:30 - 4:30 p.m. (1 CE)

##### Concentrating on Concentrations: Standardizing Oral and IV Medications for Pediatric Safety

Neli Attas, RPh, PharmD, E-C

Maryam Abdrabbo, PharmD, PGY1 Pharmacy Resident

## PROGRAM OBJECTIVES

### Updates and Controversies Surrounding Medical Cannabis:

#### What Pharmacists Need to Know

Mary Bridgeman, PharmD, BCPS, BCGP, FASCP, FNAP

Clinical Professor

Ernest Mario School of Pharmacy

Rutgers, The State University of New Jersey

Internal Medicine Clinical Pharmacist

Robert Wood Johnson University Hospital

ACPE #0152-0000-19-025-L05-P & T

#### Pharmacist:

1. Describe the pharmacology and systemic effects of cannabis
2. List potential therapeutic uses for medical cannabis
3. Explain safety concerns associated with cannabis, including adverse effects and drug interactions
4. Recognize the controversy between state and national laws as applied to cannabis regulation
5. Describe controversies surrounding medical cannabis use in the acute care setting

#### Technician:

1. Recognize potential medical uses for cannabis
2. Identify safety concerns and risks associated with cannabis use
3. Identify the federal scheduling of cannabis as a controlled substance
4. Explain why cannabis use is controversial in the acute care setting

### Medication Safety Pearls - Session 1

Maria Heaney, PharmD

Danielle Tomkins, PharmD, BCCCP

Michael T. Mauri, PharmD, BCPS

Jane You, PharmD

ACPE #0152-0000-19-024-L05-P & T

#### Pharmacist:

1. Identify the antibiotics that pose the highest risk of Clostridium difficile infection (CDI)
2. Recognize risk factors and strategies to reduce medication errors involving continuous infusions in the intensive care unit
3. Identify strategies to minimize medication errors related to anticoagulant use and dispensing
4. Summarize specific elements of performance in the 2019 Joint Commission's National Patient Safety Goal 03.05.01 regarding direct oral anticoagulants, anticoagulant reversal agents, perioperative anticoagulation management, and anticoagulation dispensing safety

#### Technician:

1. List contact precaution requirements for entering/exiting the room of a patient with CDI
2. Recognize risk factors and strategies to reduce medication errors involving continuous infusions in the intensive care unit
3. Identify strategies to minimize medication errors related to anticoagulant use and dispensing
4. Summarize specific elements of performance in the 2019 Joint Commission's National Patient Safety Goal 03.05.01 regarding direct oral anticoagulants, anticoagulant reversal agents, perioperative anticoagulation management, and anticoagulation dispensing safety

### Concentrating on Concentrations: Standardizing Oral and IV

#### Medications for Pediatric Safety

Neli Attas, RPH, PharmD, AE-C

St. Joseph's Health

Maryam Abdrabbo, PharmD, PGY1 Pharmacy Resident

St. Joseph's Health

ACPE #0152-0000-19-L05-P & T

#### Pharmacist:

1. Explain why national standardization of intravenous and oral pediatric medication concentrations can be used as an error prevention tool
2. Describe tactics designed to improve success in the implementation process of recommended concentrations
3. List common medications that have been added to the national standard concentration list
4. Identify key partners, initiatives and future directions in the development of national concentration – related medication standardization process

#### Technician:

1. List factors that contribute to improved safety of dispensing medications to children
2. Recognize institutional standard compounds ordered by prescribers
3. Identify challenges and benefits of using standard concentrations
4. List obstacles in the standardization process

### "How Low Ca(Na+) You Go? Hyponatremia Management and Patient Safety Considerations"

Jackie P. Johnston, PharmD, BCPS

St. Joseph's Health

Christine Pham, PharmD, PGY1 Pharmacy Resident

St. Joseph's Health

ACPE #0152-0000-19-026-L05-P & T

#### Pharmacist:

1. Define hyponatremia
2. Explain the etiology of hyponatremia and common causes
3. List pharmacologic agents and safety considerations with use
4. Recall appropriate treatment and monitoring plan for hyponatremia management

#### Technician:

1. Define hyponatremia
2. Explain the importance of obtaining proper medication and medical histories
3. Identify common therapies used in the management of hyponatremia
4. Recall considerations for safe dispensing practices of pharmacotherapy agents

### Medication Safety Pearls - Session 2

Umme Honey, PharmD, BCPS

Ken Bason, PharmD, BCPS

Lynette Richards, PharmD, BCPS

Safia Kuriakose, PharmD, BCPS

ACPE #0152-0000-19-028-L05-P & T

#### Pharmacist:

1. Explain the PEP regimen for occupational HIV exposure
2. Recognize high dose extended interval aminoglycoside dosing to prevent toxicity and adverse drug reactions
3. Identify medications that can precipitate delirium

4. List the treatment options for ebola virus disease that demonstrated success in the PALM trial

#### Technician:

1. Identify the drugs that are used for post-exposure prophylaxis for occupational HIV exposure
2. Name common side effects of aminoglycosides
3. Identify medications that can precipitate delirium
4. List the treatment options for ebola virus disease that demonstrated success in the PALM trial

### Medication Safety Considerations in Prostate Cancer

Christopher Malabanan, PharmD, BCPS

Clinical Pharmacist Internal Medicine and Anticoagulation

St. Joseph's Health

Kelvin Reynolds, PharmD, PGY1 Pharmacy Resident

St. Joseph's Health

ACPE #0152-0000-19-029-L05-P & T

#### Pharmacist:

1. Describe adverse drug reactions associated with medical androgen deprivation therapy (ADT)
2. Recognize major drug interactions for ADT and chemotherapy used in prostate cancer
3. Identify appropriate drug product for bone health and bone metastases

#### Technician:

1. List specific ADT medications for prostate cancer
2. List ways the technician can promote adherence of medications used for prostate cancer
3. Describe safe handling of chemotherapy and immunotherapy used in prostate cancer

### "Technology: EHR E-Utopia: Are We There Yet?"

Radhika Pisupati, PharmD, BCPS

Clinical Pharmacy Manager | Pharmacy

St. Joseph's Health

Michelle Cottino, PharmD, PGY1 Pharmacy Resident

St. Joseph's Health

ACPE #0152-0000-19-030-L05-P & T

#### Pharmacist:

1. Summarize the timeline of the EHR evolution in the United States
2. List EHR features that are fundamental to enhancing patient safety
3. Identify common errors associated with medication management in EHR
4. Identify metrics that assess EHR use and design strategies to mitigate risk of medication errors.

#### Technician:

1. Summarize the timeline of the EHR evolution in the United States
2. List EHR features that are fundamental to enhancing patient safety
3. Identify common errors associated with medication management in EHR